Clearside Biomedical is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®).
The platform provides an in-office, repeatable, non-surgical procedure, offering targeted and compartmentalized delivery to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
Our suprachoroidal injection technology can be used in conjunction with existing drugs designed for the SCS, novel therapies, and future therapeutic innovations. We are developing a pipeline of small molecule product candidates for administration via our SCS Microinjector®, and we are also looking to strategically partner with companies utilizing other ophthalmic therapeutic innovations. We believe our proprietary suprachoroidal administration platform has the potential to become a standard for delivery of therapies intended to treat chorioretinal diseases.